Note: Ingredients listed on restricted chemical lists
EC/CAS
231-633-2/7664-38-2
Name of the chemical
phosphoric acid
Concentration
**
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
*
General Information
Version
1.0
Revision date
2012-01-03
Product name
Cladribine Injection
Product name
Cladribine Injection
Identification on the label/Trade name
Not applicable
Chemical name
Mixture
1.2.1 Relevant identified uses
Pharmaceutical product used as Antineoplastic
Emergency telephone
1-800-424-9300, +1-703-527-3887
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
GHS Information
Signal word
DANGER
Hazard Codes
Hazard statements (CLP)
H341
Hazard statements
Code
Statements
H341
Suspected of causing genetic defects
Section 2
SECTION 2: Hazards identification
Appearance Colorless solution
Signal word
DANGER
Hazard statements
Suspected of causing genetic defects.
Additional information
Short Term May cause eye and skin irritation (based on components) . Long Term Animal studies have shown a potential to cause adverse effects on the fetus. Known Clinical Effects Bone marrow suppression is the most serious adverse effect seen during clinical use. Adverse effects seen in clinical use include gastrointestinal discomfort, dizziness, and headache. EU Indication of danger Mutagenic: Category 2 EU Hazard Symbols EU Risk Phrases R46 - May cause heritable genetic damage. Australian Hazard Classification (NOHSC): Note
Hazardous Ingredients
Non-Dangerous Goods This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
